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The Lyon-Marseille-Curie-Est (LMCE) of France cooperative group has previously reported successive series of unselected
stage four children older than 1 year at diagnosis with metastatic neuroblastoma (LMCE 1 and 3). The goal of LMCE 5 study
was to increase progression free survival rate as compared to LMCE 1 and 3. Based on improvements reported with post
induction chemotherapy, the LMCE 5 used post induction for all children, but omitted total body irradiation and
immunomagnetic purging in megatherapy regimen for all children. Twenty-ﬁve sequentially diagnosed children received an
induction regimen which compared with previous induction included an increased dose of etoposide and cyclophosphamide,
delivered similar dose of cisplatinum, and deleted doxorubicin and vincristin. After surgery treatment was stratiﬁed based on
response and eligible children received etoposide carboplatin (LMCE 5A:n=10)+doxorubicin (LMCE 5B–C n=13) followed
by megatherapy (melphalan without total body irradiation and unpurged peripheral blood stem cell rescue). The increase in
drug doses during induction did not improve remission rate. The progression free survival at 6 years is 8%. It is signiﬁcantly
worse than LMCE 3, and equivalent to LMCE 1 study though toxic death rate has decreased with increasing experience.
Failure to improve the response rate during induction and reducing the megatherapy regimen may be the main factors in this
disappointing result. Modiﬁed strategies for induction, non toxic alternative to total body irradiation, and post megatherapy
regimen should be developed.
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Metastatic neuroblastoma (NB) occurring in children older than 1
year remains a challenge in pediatric oncology, although the survi-
val rate of children has progressively increased during the past 20
years (Hartmann et al, 1983; Berthold et al, 1997; Castleberry et al,
1997). Increased doses during induction chemotherapy and/or
megatherapy consolidation may both account for this improve-
ment. More recently, the introduction of innovative post
consolidation treatment by non cytotoxic drugs (such a retinoic
acid) has clariﬁed the role of this biological agent, but may further
complicate the interpretation of improved survival curves (Matthay
et al, 1999). The Lyon-Marseille-Curie East of France group
(LMCE) previously published the LMCE1 and LMCE3 studies.
These concerned unselected cohorts of children successively seen
at diagnosis with metastatic NB (Philip et al, 1987, 1991; Frappaz
et al, 2000). The LMCE1 used a single strategy: all patients received
similar induction chemotherapy followed by surgery and a vincris-
tine–melphalan–Total Body Irradiation (TBI) consolidation
regimen in chemosensitive patients (Philip et al, 1987, 1991). This
study and the report of the European Bone Marrow Transplanta-
tion Study Group (Ladenstein et al, 1993) suggested that
clearance of skeletal uptake on bone scan after induction therapy
deﬁnes a better prognosis subgroup that contains 40% of the
population and have a 40% PFS at 5 years (versus 10%). The
LMCE3 used a higher dose-intensity during induction (doubling
of cisplatin dose) (Coze et al, 1997) followed by a similar consoli-
dation regimen. For patients who were not in remission of
metastases, post induction chemotherapy was delivered prior to
consolidation (Frappaz et al, 1992; Philip et al, 1993). It included
either a VP-carboplatinum combination or a ﬁrst megatherapy.
Overall, the 7 years PFS of this cohort was 29%. This was signiﬁ-
cantly better than the LMCE1 results (8% at 14 years) and than
historical controls (10% at 5 years). It suggested that increasing
induction and delivering post induction therapy prior to megather-
apy was worthwhile. However, when the cure rate increases, quality
of life becomes a predominant problem. Total Body Irradiation is
responsible for many long term toxicities that may become unac-
ceptable (Neve et al, 1999; Peper et al, 2000).
The LMCE5 strategy reported here was thus designed to: (1)
Further increase total dose and dose intensity of cyclophosphamide
and etoposide during induction, with deletion of anthracyclines;
(2) Deliver post induction to every patient, and modify the regi-
men in poor responders; (3) Decrease late sequelae by omitting
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PATIENTS AND METHODS
From December 1992 to April 1995, every patient older than one
year with stage 4 NB admitted in the LMCE institutions of Lyon
(Centre Le ￿on Be ￿rard), Marseille (Ho ˆpital de la Timone), Curie
Institute (Paris), and St. Etienne (Ho ˆpital Nord) entered in the
LMCE5 strategy (n=25). Staging at diagnosis and during follow-
up followed International Neuroblastoma Staging System recom-
mendations (Brodeur et al, 1993).
Patients
Pretreatment investigations included: complete physical examina-
tion, full blood count, renal and hepatic function tests, serum
LDH NSE and ferritin, and urinary catecholamine determinations.
Bone marrow involvement was assessed as previously described
using at least two interpretable smears and two interpretable bone
marrow biopsies and immunological pool (Favrot et al, 1986).
MYCN ampliﬁcation was determined on the primary by open or
ﬁne needle biopsy or on the metastatic sites. MIBG scan and
measurements of primary and metastatic lesions by ultrasonogra-
phy and/or CT scan were performed as required. Technecium
bone scan was mandatory only in patients with no MIBG uptake.
Response rate and remission status were evaluated after each
step of the strategy (induction, post induction and megatherapy).
The International Neuroblastoma Response Criteria were used to
deﬁne response as follows: a complete response (CR) was deﬁned
as the disappearance of signs of tumour in both primary and meta-
static sites. A continuous complete remission (CCR) was deﬁned as
patients who remained in CR. A very good partial remission
(VGPR) was deﬁned as a 490% response locally and a complete
response elsewhere. A partial response (PR) was deﬁned as more
than 50% reduction in both size of the primary tumor and number
of metastatic lesions. All regression of tumour 550% were consid-
ered as no response (NR). A progressive disease (PD) as more than
25% increase in the size of measurable lesions at any involved site
and/or appearance of new lesions. A mixture of CR and/or PR and
NR without progression, was deﬁned as mixed response (MR). The
response rate was deﬁned as the percentage of CR+VGPR+PR
among evaluable patients.
Toxicity was assessed at each step and during the 100 days
following consolidation, according to WHO criteria (World Health
Organization, 1979).
Treatment
All patients included in the LMCE5 strategy received induction
therapy with the NB92 protocol (Figure 1).
The induction regimen comprised two cycles alternating CE
(Cyclophosphamide (Endoxan
1 2000 mg m
72 per day, Days 2–
4 as a 1 h infusion), Etoposide (Vepeside
1 50 mg m
72, Days
1–5 as a continuous infusion) with etoposide-cisplatinum (Vepe-
side
1 100 mg m
72 as a 1 h infusion and cisplatinum
40 mg m
72 days 1–5 as a continuous infusion), delivered at 3
week intervals.
Patients with progressive disease during induction were excluded
from further LMCE5 strategy. All other patients underwent surgery
after completion of induction. Local radiotherapy was not to be
given in this protocol. All underwent steady state collection of
autologous peripheral blood stem cell without purging after
completion of induction.
The post induction strategy was tailored according to remission
status. The patients in CR-VGPR (LMCE5A) received two courses
of etoposide-carboplatin (Vepeside
1 100 mg m
72 and carboplatin
160 mg m
72 Days 1–5) and proceeded to consolidation by high
dose melphalan (200 mg m
72) with progenitor rescue following
surgery.
All other patients underwent a phase II study with two courses
of Doxorubicin (Adriamycine
1 90 mg m
72 in continuous infu-
sion). Non progressive patients then received two courses of
etoposide-carboplatin followed by consolidation by high dose
melphalan (200 mg m
72) with progenitor rescue (LMCE5B)
following surgery. For patients who did not respond to doxorubi-
cin, no further guidelines were proposed but patients could be
treated with a similar strategy (LMCE5C). Follow-up strategy used
routine CT scan, MIBG and catecholamine assessment.
Statistical analysis
The main aim of this pilot study was to improve survival by giving
a combination of post induction strategy adjusted for initial
response while decreasing consolidation regimen to improve qual-
ity of survival. Objectives were to study Overall Survival (OS),
Progression Free Survival (PFS) and toxicity into the three conso-
lidation groups deﬁned prior post-induction, i.e. LMCE5A, 5B and
5C. The intent was to include every child with newly diagnosed
metastatic neuroblastoma in a period of 2 years. A stopping rule
on toxic death was established. OS and PFS distributions were esti-
mated using the Kaplan–Meier method (Kaplan and Meier, 1958),
and compared by the log-rank test (Mantel, 1966). Survival time
was deﬁned as the time from the date of diagnosis to the date of
death (OS), disease progression or death regardless of cause
(PFS) or last follow-up date. All analysis were performed with
the SPSS statistical software package (SPSS Inc., Chicago, IL,
USA). These data were compared with historical series issued from
the same group: LMCE1 (updated) and LMCE3. In the LMCE1,
most patients had skeletal assessment with technecium while in
LMCE3, all had MIBG.
RESULTS
From December 1992 to April 1995, 25 patients older than one
year were admitted for untreated stage 4 NB in the LMCE partici-
pating institutions. No stage 3 patient was included. No patient
was excluded.
Sex ratio was seven females/18 males. Median age at diagnosis
was 31 (13–167) months. This was not different from previous
LMCE 1 and 3 cohort: P=0.39. Primary tumour was in retroperi-
toneum (22), soft tissues of thorax and axillar (1), or absent (2). Its
size using INSS criteria was T1 (3), T2 (10), T3 (10), TX (2).
Serum levels of LDH were raised in 24 out of 25 (median 1340
ui; 383–6086), ferritin in 13 of 19 (265 mg ml
71; 80–1000) and
Neuron Speciﬁc Enolase in 21 of 21 (142 mg ml
71: 31–622).
Urinary levels of catecholamine were raised in 24 of 25, with
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Figure 1 Summary of the protocol.
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71 of creatinin, 3–350), VMA
(25 mmol mmol
71, 2–414) and dopamine (4754 mmol mmol
71,
86–48223). Shimada classiﬁcation was not determined since
chemotherapy was delivered prior to surgery. MYCN was ampliﬁed
in seven out of 24 tested patients (all more than 10 copies).
Tumour was diploid in nine out of 12 tested patients.
The MIBG scans used I
123 in 14 patients and I
131 in 11 patients.
Skeletal uptake was detected by MIBG (21 patients) or technecium
bone scan only (one patient). Twenty-four had bone marrow inva-
sion. One patient had neither bone, nor bone marrow involvement
but an abdominal mass with thoracic metastases. Other metastatic
sites included thorax (one), distant lymph nodes (two).
These data were comparable to that of our previous prospective
protocols (LMCE1 and 3) as far as age, sex, LDH levels, MYCN
ampliﬁcation at diagnosis.
Response
Induction therapy Twenty-ﬁve patients received at least one
course and 24 patients received the four courses of the induction
regimen (one patient with renal toxicity of cisplatinum was
excluded from further LMCE5 strategy). The response rate prior
to surgery was 19 out of 24 (CR in one, VGPR in one, and PR
in 17 patients). Response rate was 20 out of 22 for primary
tumours, 23 out of 24 (96 %) for bone marrow invasion and in
eight out of 21 (38%) of evaluable skeletal MIBG uptake had
completely disappeared. This rate of complete skeletal uptake
normalisation did not differ from LMCE1 (35 out of 72: P=0.4)
and LMCE3: (48 out of 99: P=0.39).
Surgery Three patients had undergone frontline surgery of the
primary (n=2), or for spinal compression (n=1). Out of 21 patients
who were operated after induction, the tumour was completely
removed (n=13), or only partially resected (n=8). A nephrectomy
was required in four out of 20 of patients with abdominal
primaries. One patient died of surgical related complication (the
operative resection was not evaluable).
The response rate after induction and surgery was 20 out of 23
with ﬁve CR, three VGPR, 12 PR (10 had persistent skeletal
uptake), two MR-NR and one PD (all had persistent skeletal
uptake).
Post-induction strategy Two patients did not fulﬁl the require-
ments for inclusion in the post induction strategy. The ﬁrst one
had toxicity of cisplatinum during induction, that was replaced
by carboplatin. He then received megatherapy by busulfan–
melphalan, and relapsed at 8 months post diagnosis. The other
one was a post surgical death.
Twenty three patients were considered to ﬁt with the require-
ments for post induction strategy. LMCE5A was delivered to 10
patients. Status prior to post induction was: CR (n=5), VGPR
(n=3), PR (n=2 by protocol violation). Status post consolidation
was:CCR (n=5), CR (n=2), VGPR (n=2), PD (n=1). Eight patients
eventually progressed and died of disease, two patients are alive
disease free. These two patients were 1 and 4 years old at diagnosis
respectively. Both underwent initial surgery, and had metastasis in
bone marrow and skeleton at diagnosis; one had MYCN ampliﬁca-
tion.
LMCE5B was delivered to 10 patients who were all in PR. Status
post consolidation was: CR (n=3), PR (n=5) and PD (n=1). One
patient died of adenoviral infection during Doxorubicin. Eight
patients eventually progressed and died of disease, one patient is
alive in partial remission.
LMCE5C was used in three patients. Status prior to post induc-
tion was NR (n=2) or PD (n=1). None of these patients responded
to the post induction-consolidation strategy and all ultimately
progressed and died.
Doxorubicin activity could be evaluated in 12 patients (one
patient further died of acute adenoviral infection) and resulted in
two complete remissions (16%), one partial remission, six stable
disease and three progressive disease. The response rate is thus
three out of 12 evaluable patients.
All together, the site of relapse was exclusively primary in only
one out of 19 patients: ﬁve out of 19 (26%) had local progression,
18 out of 19 (95%) metastatic progression.
Progression free survival
The Progression free survival (PFS) in the unselected cohort of 25
patients is 8% at 6 years from diagnosis. There was no difference
on univariate analysis between patients in CR-VGPR after induc-
tion vs others, nor those who had cleared their skeletal uptake
after induction therapy, nor those more or less than 2 years old
at diagnosis. These results compare with a similar cohort of 72
patients previously reported by our group (LMCE1 8% of PFS at
14 years) (Philip et al, 1991). However, it is worse than the cohort
of 99 patients included in LMCE3 study: 29% at 7 years from diag-
nosis: P50.07 (Figure 2) (Frappaz et al, 2000). The toxic death
rate was decreased with time: 22% (16 out of 72 patients), 10%
(10 out of 99 patients) and 4% (one out of 25 patients) in respec-
tively LMCE1, 3 and 5. If only the subgroup of patients who
showed normalisation of skeletal uptake after induction are
analysed, the progression free is respectively 12, 50 and 20%
(Figure 3) and the toxic death rate 35, 3 and 0% for LMCE1, 3
and 5. There was no difference in PFS between children with or
without MYCN ampliﬁcation.
DISCUSSION
The LMCE cooperative group organised three successive studies
(LMCE1, 3 and 5). The aim of these studies was to enrol every
child presenting with metastatic neuroblastoma in each of the
participating institutions and in this way to report unbiased series.
The LMCE1 study reported a cohort of 72 children, who received
standardised induction and megatherapy (Philip et al, 1987, 1991).
It demonstrated that after induction, the subgroup of children who
showed persistent signs of metastases on bone scan had signiﬁ-
cantly shorter survival. The LMCE3 study was built on such
ﬁnding (Frappaz et al, 2000). It included 99 children. After induc-
tion, children with negative MIBG uptake on skeleton immediately
proceeded to megatherapy (LMCE3A), while those with persisting
skeleton uptake received a post induction cycle prior to megather-
apy (LMCE3B-C). The LMCE3 resulted in signiﬁcantly improved
PFS as compared to LMCE1. The improvement was mainly attri-
butable to decrease in toxic death rate and increased PFS in the
subgroup of poor prognosis children who had received post induc-
tion therapy. Thus, LMCE5 incorporated post induction therapy
for all children but removed TBI from conditioning regimen.
The results are much worse than in LMCE3 study and the possible
reasons for this failure will be discussed.
The populations treated in all three successive studies are
comparable as far as age, sex and biological characteristics are
concerned (Brodeur et al, 1997). The population is equally divided
between those more and less than 2 years at diagnosis. Nearly all
children had increased LDH, and one-third MYCN ampliﬁcation.
Two-thirds were diploid. Twenty-two children had skeletal involve-
ment.
The induction was modiﬁed in the successive LMCE studies.
The LMCE3 induction delivered twice as much cisplatinum as in
LMCE1 induction that used a combination of all drugs shown to
be useful in a metaanalysis (Cheung and Heller, 1991). Both induc-
tions resulted, however, in a similar rate of remissions, especially at
skeletal sites. The LMCE5 induction gave similar total dose of
cisplatinum though with lower dose intensity. The main objective
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1197–1203of this induction was to test a dose effect relationship of etoposide
and cyclophosphamide (Meresse et al, 1993). The total dose of
etoposide and cyclophosphamide was increased 2–4-fold (Table
1). Doxorubicin was deleted only in the favourable group
(LMCE5A) and vincristine was omitted for all patients. Here again,
the rates of remission were similar, especially on skeleton sites.
During the same period, another French cooperative group
proposed a similar protocol including doxorubicin, and reached
similar results (Plantaz, personal communication). More intensive
and prolonged induction strategies have been published, claiming
an increased remission rate (Kushner et al, 1994). However,
increased toxicity was reported. Moreover, these results could not
be reproduced by the SFOP group (Valteau-Coinet, personal
communication). Thus the dramatic improvements described in
high grade lymphoma by increasing the dose of known drugs
during induction therapy cannot be translated to metastatic neuro-
blastoma (Patte et al, 1994). It thus seems unlikely that further
intensiﬁcation of induction may result in major improvement of
remission rate, as it did not change between three successive
cohorts, but this issue is addressed in the recently completed
ENSG5 study which compares standard dose of OPEC/OJEC with
the rapid COJEC regimen (Pinkerton et al, 2000). Either new drugs
are to be found, or different scheduling is used, or improvements
will come from novel strategies.
Surgical resection was complete in 13 of 21 patients, and one
patient died of surgical complications. Much cooperative work has
been done in France, between surgeons, radiologists and oncologists,
to predict surgical difﬁculties in localised neuroblastomas (Rubie et
al, 1998). This has also probably improved surgical management in
metastatic disease and explains the low rate of nephrectomy (four
out of 20 abdominal procedures). Despite the surgical death
reported here, it is unlikely that changes in surgery could be respon-
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Figure 2 Progression free survival of the three successive LMCE cohorts:LMCE1–3–5.
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Figure 3 Progression free survival of the favourable subgroup of patients with clearance of skeletal uptake post induction in the three successive LMCE
cohorts:LMCE1–3–5.
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relapse may reﬂect the absence of radiation either locally or through
a TBI. The role of local radiation has however never been demon-
strated by randomised studies in this setting.
Ten patients were included in LMCE5A favourable group. Eight
out of these 10 progressed or relapsed, giving a 6 years PFS of only
20%. In the LMCE1 and LMCE3 patients this favourable subgroup
received no post induction, but a vincristine, melphalan-TBI
conditioning followed by immunobead purged marrow rescue.
The PFS of these patients was 12% in LMCE1 and 50% at 7 years
in LMCE3. Although numbers are small, the comparison between
the successive favourable groups deserves several comments. There
was no selection bias in the LMCE5. Eight out of 10 were in CR-
VGPR and none had persisting skeletal involvement in LMCE5A
whereas in LMCE3A only 27 out of 32 were in CR-VGPR and
two had persisting skeletal uptake. Due to better selection in
LMCE5A than in LMCE3A patients should have had a better survi-
val. The use of post induction was suggested as improving outcome
in LMCE3B patients compared to the LMCE1 and was thus
proposed to all LMCE5 patients. A part from Doxorubicine and
vincristine omission, the total amount of chemotherapy delivered
prior to megatherapy was thus higher in the LMCE5A. The total
duration of treatment was thus longer in LMCE5 A (18 weeks)
and apart from cisplatinum dose intensity was higher than in
LMCE3A (12 weeks). However, LMCE5A patients had poorer
survival than the comparable subgroup of LMCE3A patients.
The other patients were included in LMCE5B (n=10) or C
(n=3). Though anthracyclines are quoted as a major drug in meta
analysis (Cheung and Heller, 1991), its exact role was challenged
(Ninane et al, 1981). We thus took the opportunity to test it in
resistant patients. After two cycles of doxorubicin, the response rate
(three out of 12) suggests that adriamycin is an active agent in
neuroblastoma. However due to small number of patients (less
than 14), the classical Gehan rule cannot be applied, and we cannot
reliably insure that response rate is more than 20%. All of these 13
patients are currently progressing or dead. The inﬂuence of
Vincristine deletion may also be discussed as it may be a potent
inhibitor of neoangiogenesis (Avramis et al, 2001).
Probably of importance is the deletion of total body irradiation.
This had been decided both in view of the late effects of radiations
in young children (Neve et al, 1999; Peper et al, 2000) and on the
circumstantial evidence from the EBMT database that TBI does
not, in fact, seem to improve the outcome (Ladenstein et al,
1998). We had hypothesised that it might be replaced by introduc-
tion of post induction therapy and a small increase in melphalan
dose. We suggest here that this is not the case, though several
modiﬁcations may also have contributed. In view of marked
improvements in supportive measures and in view of well-docu-
mented synergistic antitumor effects between 2–3 agents, there is
no reason today to limit megatherapy to a single agent.
The role of megatherapy has been largely debated. Some non
randomised studies show promising results with prolonged inten-
sive standard chemotherapy without massive chemotherapy
(Kushner et al, 1994). Two randomised studies suggest that mega-
therapy signiﬁcantly increases the chance of deﬁnitive cure. In a
prospectively randomized high risk group of responding patients,
a signiﬁcant advantage for the group treated with high dose
Melphalan was demonstrated (Pinkerton, 1991). More recently,
the CCG conﬁrmed that high risk neuroblastoma beneﬁted from
high dose regimen including TBI and followed by purged autolo-
gous marrow reinfusion (Matthay et al, 1999). Though there is
no clear evidence that TBI containing regimens provide better
results than melphalan alone (Ladenstein et al, 1998), this is
suggested from LMCE5. We had discarded TBI in view of the late
sequelae observed in young children: endocrinopathies, growth
delays, pulmonary dysfunction, ocular toxicities. The dilemma is
thus whether TBI induced sequelae sufﬁciently severe to justify a
clear decrease in survival or can TBI be replaced by something else?
The answer may be with busulfan containing regimens (Hartmann
et al, 1999) or from tandem therapies as used in some LMCE3
patients (Philip et al, 1993; Grupp et al, 2000). However, high dose
busulfan is responsible for acute visceral toxicities, and for delayed
endocrinological toxicities (Hartmann et al, 1987). Longer follow-
up is probably warranted to ensure that no unexpected delayed
effect will appear.
A ﬁnal difference between LMCE1-3 and LMCE5 should be
considered. In the latter protocol, immunobead purging (Combar-
et et al, 1989) was omitted. Potentially contaminated progenitor
collection remains an unsolved problem. The demonstration that
neomycin resistance gene transfected genes in reinfused marrow
may be detected in relapsed disease suggests that contaminated
marrow may at least contribute to further relapse (Rill et al,
1994). Moreover, pulmonary (Glorieux et al, 1986) or intracranial
(Frappaz et al, 1994) relapses after ABMT may suggest that rein-
fused malignant cells are clonogenic in vivo. However, the type of
relapses observed in this study were not unusual. The ideal study
randomising purged vs unpurged marrow, or autologous versus
allogenic rescue is lacking. The possible role in the poor results
of lack of therapy for minimal residual disease should be stressed.
However, the positive results of the randomised CGG study
(Matthay et al, 1999) was not known at that time. Moreover,
none of previous LMCE strategies had incorporated such treat-
ment.
It may thus be concluded that in stage IV neuroblastoma more
than 1 year old at diagnosis, the dose effect during induction has
been fully explored in the last 20 years without major improve-
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Table 1 Doses of chemotherapy in successive LMCE studies in mg m
72 (mg m
72 week
71)
LMCE3 LMCE5
LMCE1 A B A B
VM26 320 (26) 0 0 0 0
Etoposide mg 0 1000 (83) 2000 (111) 2500 (138) 2500 (104)
Cisplatinum mg 200 (16) 400 (33) 400 (22) 400 (22) 400 (16)
Carboplatin mg 0 0 1600 (88) 1600 (88) 1600 (66)
Vincristin mg 7 (0,58) 7 (0,58) 7 (0,38) 0 0
Cyclophosphamide mg 3000 (25) 3000 (250) 3000 (166) 12000 (666) 12000 (500)
Doxorubicin mg 120 (10) 120 (10) 120 (6,6) 0 180 (7,5)
Melphalan mg 140 (11,6) 180 (15) 180 (10) 200 (11) 200 (11)
TBI gy 12 12 12 0 0
Duration (weeks) 12 W 12 W 18 W 18 W 24 W
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1197–1203ments. The time to explore alternative schedules during induction
may have come. The deletion of TBI in a strategy based on conso-
lidation by megatherapy may be detrimental. The addition of post
megatherapy treatment such as with novel retinoids and passive or
active immunotherapy requires exploration.
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